HLB Co. Ltd (KQ:028300) — Market Cap & Net Worth
Market Cap & Net Worth: HLB Co. Ltd (028300)
HLB Co. Ltd (KQ:028300) has a market capitalization of $5.41 Billion (₩7.98 Trillion) as of May 3, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #3396 globally and #86 in its home market, demonstrating a 0.33% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HLB Co. Ltd's stock price ₩60800.00 by its total outstanding shares 131198038 (131.20 Million). Analyse 028300 cash flow conversion to see how efficiently the company converts income to cash.
HLB Co. Ltd Market Cap History: 2015 to 2026
HLB Co. Ltd's market capitalization history from 2015 to 2026. Data shows growth from $751.97 Million to $5.41 Billion (19.11% CAGR).
Index Memberships
HLB Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$299.07 Billion | 1.81% | #6 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$299.07 Billion | 1.81% | #6 of 1384 |
Weight: HLB Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
HLB Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HLB Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.10x
HLB Co. Ltd's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $751.97 Million | $38.46 Billion | $12.64 Billion | 0.02x | 0.06x |
| 2016 | $457.80 Million | $30.14 Billion | -$13.21 Billion | 0.02x | N/A |
| 2017 | $1.35 Billion | $23.01 Billion | -$16.53 Billion | 0.06x | N/A |
| 2018 | $2.78 Billion | $36.19 Billion | $25.34 Billion | 0.08x | 0.11x |
| 2019 | $4.00 Billion | $38.42 Billion | -$44.39 Billion | 0.10x | N/A |
| 2020 | $3.64 Billion | $56.18 Billion | -$80.09 Billion | 0.06x | N/A |
| 2021 | $2.74 Billion | $69.83 Billion | -$98.13 Billion | 0.04x | N/A |
| 2022 | $2.40 Billion | $179.71 Billion | -$78.16 Billion | 0.01x | N/A |
| 2023 | $4.51 Billion | $42.90 Billion | -$187.55 Billion | 0.11x | N/A |
| 2024 | $6.50 Billion | $68.13 Billion | -$91.98 Billion | 0.10x | N/A |
Competitor Companies of 028300 by Market Capitalization
Companies near HLB Co. Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to HLB Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
HLB Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, HLB Co. Ltd's market cap moved from $751.97 Million to $ 5.41 Billion, with a yearly change of 19.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩5.41 Billion | +19.69% |
| 2025 | ₩4.52 Billion | -30.51% |
| 2024 | ₩6.50 Billion | +44.18% |
| 2023 | ₩4.51 Billion | +87.45% |
| 2022 | ₩2.40 Billion | -12.09% |
| 2021 | ₩2.74 Billion | -24.76% |
| 2020 | ₩3.64 Billion | -9.11% |
| 2019 | ₩4.00 Billion | +43.80% |
| 2018 | ₩2.78 Billion | +106.73% |
| 2017 | ₩1.35 Billion | +193.92% |
| 2016 | ₩457.80 Million | -39.12% |
| 2015 | ₩751.97 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of HLB Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.41 Billion USD |
| MoneyControl | $5.41 Billion USD |
| MarketWatch | $5.41 Billion USD |
| marketcap.company | $5.41 Billion USD |
| Reuters | $5.41 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HLB Co. Ltd
HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber pipes in South Korea and internationally. It engages in the repair and inspection of lifeboats; fabrication and installation of pipes; development and manufacturing of biopharmaceuticals products, such as anti-cancer drugs; and manufacture and sale of medical devices, as well as manufacture and sale of quasi-drugs products, inclu… Read more